Pegzilarginase, first disease-modifying therapy for Arginase 1 deficiency, lowers toxic arginine levels, slows neurological damage, and transforms care through enzyme replacement, accelerated approval, and multidisciplinary support.

Fenebrutinib, an oral BTK inhibitor, shows non-inferiority to ocrelizumab in PPMS, targeting CNS inflammation, reducing infusion burden, and expanding equitable, scalable progressive multiple sclerosis care.

Serial symptom monitoring and targeted screening improve early tuberculosis detection, enabling faster diagnosis, reduced transmission, smarter triage, and timely treatment for high-risk and underserved populations worldwide.

Managing lipids in CKD, HIV, and cancer requires individualized therapy, careful drug interaction monitoring, multidisciplinary coordination, and balanced cardiovascular prevention to ensure safety, adherence, and long-term outcomes.

Cholesterol therapy adherence ensures long-term cardiovascular protection by promoting consistent medication use, addressing barriers, improving care coordination, reducing disparities, and preventing avoidable heart attacks, strokes, and healthcare costs.

MyLungHealth integrates with EHR workflows to identify lung cancer screening eligibility, increase low-dose CT orders, enhance early detection, and improve outcomes for high-risk primary care patients.

Emerging MASLD and MASH treatments emphasize multidisciplinary collaboration, improving early detection, coordinated care, and disease management for patients with metabolic disorders while reducing progression and healthcare burden.

Early cognitive screening after ischemic stroke helps predict return-to-work potential, guiding rehabilitation planning, aligning expectations, and improving functional recovery through integrated cognitive and vocational care strategies.

Optical Genome Mapping improves genetic risk assessment in myelofibrosis, enabling personalized treatment decisions, earlier intervention, better monitoring, and more efficient healthcare resource use for high-risk patients.

Blood-based Alzheimer’s biomarkers enable earlier, less invasive diagnosis, expanding screening and research opportunities while raising concerns about accuracy, equity, access, counseling, and health system readiness for implementation.